Last reviewed · How we verify
Ex-vivo expanded effector cells
Ex-vivo expanded effector cells is a Cell therapy Biologic drug developed by Dartmouth-Hitchcock Medical Center. It is currently in Phase 2 development.
Immune effector cells are collected from patients, expanded in laboratory culture to increase their numbers, then reinfused to enhance immune response.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ex-vivo expanded effector cells |
|---|---|
| Sponsor | Dartmouth-Hitchcock Medical Center |
| Drug class | Cell therapy |
| Modality | Biologic |
| Phase | Phase 2 |
Mechanism of action
The therapy involves harvesting immune effector cells from a patient, culturing them ex-vivo to dramatically increase their population, and then reinfusing the expanded cells back into the patient. This approach aims to boost the patient's immune system by providing a larger army of functional immune cells.
Approved indications
Common side effects
Key clinical trials
- Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma (PHASE2)
- Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ex-vivo expanded effector cells CI brief — competitive landscape report
- Ex-vivo expanded effector cells updates RSS · CI watch RSS
- Dartmouth-Hitchcock Medical Center portfolio CI
Frequently asked questions about Ex-vivo expanded effector cells
What is Ex-vivo expanded effector cells?
How does Ex-vivo expanded effector cells work?
Who makes Ex-vivo expanded effector cells?
What drug class is Ex-vivo expanded effector cells in?
What development phase is Ex-vivo expanded effector cells in?
Related
- Drug class: All Cell therapy drugs
- Manufacturer: Dartmouth-Hitchcock Medical Center — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing